$NNOXOct 16, 2026, 4:05 PM ETAI processed
NNOX: Preliminary Q3 revenue $4.3-4.4M; cash ~$26M, going-concern flagged
AI Summary
Nanox reported preliminary unaudited Q3 2026 revenue of approximately $4.3–4.4M (vs $3.4M a year ago), driven by ~$3.1M in teleradiology, $1.0M in AI/software (largely from consolidation of Vaso Health IT) and ~$0.3M in imaging/OEM sales; the company also announced a distribution deal in Italy for its Bone AI and Nanox.ARC X was named a TIME Best Invention of 2026. Management said cash, cash equivalents and deposits were about $26M as of Sept. 30 (down from $60M at year-end 2025), are not sufficient to fund operations for at least one year under current plans, and therefore raise substantial doubt about the company's ability to continue as a going concern without additional financing.
Positives
- Preliminary Q3 revenue rose to ~$4.3–4.4M vs $3.4M year-ago
- AI/software revenue increased to ~$1.0M, driven by consolidation of Vaso Health IT
- Signed distribution agreement to commercialize Nanox.AI Bone solution in Italy
Negatives
- Cash, cash equivalents and deposits declined to ~ $26M as of Sept. 30, 2026 (from $60M at 12/31/25)
- Management says cash is not sufficient to fund operations for at least one year and flags substantial doubt about going concern
- Preliminary financial data are unaudited and may change materially on final close